Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
39
MNPR Quote, Financials, Valuation and Earnings
Last price:
$62.76
Seasonality move
:
-12.16%
Day range:
$61.68 - $66.65
52-week range:
$24.00 - $105.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.97x
Volume:
325.7K
Avg. volume:
262.8K
1-year change:
157.56%
Market cap:
$421M
Revenue:
--
EPS (TTM):
-$3.44
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MNPR
Monopar Therapeutics, Inc.
|
-- | -$0.74 | -- | -97.98% | $112.00 |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$17.8M | -- | 11.04% | -- | $36.00 |
|
INFU
InfuSystem Holdings, Inc.
|
$34.6M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$806.3K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MNPR
Monopar Therapeutics, Inc.
|
$63.00 | $112.00 | $421M | -- | $0.00 | 0% | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8400 | $12.3077 | $211.1M | -- | $0.00 | 0% | 192.56x |
|
ELMD
Electromed, Inc.
|
$28.80 | $36.00 | $240.2M | 30.98x | $0.00 | 0% | 3.84x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.67 | $14.20 | $176.3M | 33.15x | $0.00 | 0% | 1.30x |
|
VNRX
VolitionRX Ltd.
|
$0.33 | $2.20 | $40.9M | -- | $0.00 | 0% | 22.82x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.68 | $1.50 | $95.5M | 66.86x | $0.00 | 0% | 0.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MNPR
Monopar Therapeutics, Inc.
|
0.05% | 3.718 | 0.01% | 55.94x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.105 | -- | 4.58x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MNPR
Monopar Therapeutics, Inc.
|
-- | -$4.1M | -31.61% | -31.63% | -- | -$2.1M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Monopar Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns MNPR or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of -12425.36%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital MNPRMonopar Therapeutics, Inc.-- -$0.48 $141.6M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About MNPR or CATX?
Monopar Therapeutics, Inc. has a consensus price target of $112.00, signalling upside risk potential of 77.41%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 333.37%. Given that Perspective Therapeutics, Inc. has higher upside potential than Monopar Therapeutics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Monopar Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNPRMonopar Therapeutics, Inc.10 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is MNPR or CATX More Risky?
Monopar Therapeutics, Inc. has a beta of 1.457, which suggesting that the stock is 45.666% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock MNPR or CATX?
Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNPR or CATX?
Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Monopar Therapeutics, Inc.'s net income of -$3.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 192.56x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNPRMonopar Therapeutics, Inc.-- -- -- -$3.4M CATXPerspective Therapeutics, Inc.192.56x -- $209K -$26M
-
Which has Higher Returns MNPR or ELMD?
Electromed, Inc. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of 12.65%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital MNPRMonopar Therapeutics, Inc.-- -$0.48 $141.6M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About MNPR or ELMD?
Monopar Therapeutics, Inc. has a consensus price target of $112.00, signalling upside risk potential of 77.41%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25%. Given that Monopar Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Monopar Therapeutics, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNPRMonopar Therapeutics, Inc.10 0 0 ELMDElectromed, Inc.4 0 0 -
Is MNPR or ELMD More Risky?
Monopar Therapeutics, Inc. has a beta of 1.457, which suggesting that the stock is 45.666% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.
-
Which is a Better Dividend Stock MNPR or ELMD?
Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNPR or ELMD?
Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Monopar Therapeutics, Inc.'s net income of -$3.4M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 3.84x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNPRMonopar Therapeutics, Inc.-- -- -- -$3.4M ELMDElectromed, Inc.3.84x 30.98x $16.9M $2.1M
-
Which has Higher Returns MNPR or INFU?
InfuSystem Holdings, Inc. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of 6.19%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital MNPRMonopar Therapeutics, Inc.-- -$0.48 $141.6M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About MNPR or INFU?
Monopar Therapeutics, Inc. has a consensus price target of $112.00, signalling upside risk potential of 77.41%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 63.78%. Given that Monopar Therapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Monopar Therapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNPRMonopar Therapeutics, Inc.10 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is MNPR or INFU More Risky?
Monopar Therapeutics, Inc. has a beta of 1.457, which suggesting that the stock is 45.666% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock MNPR or INFU?
Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNPR or INFU?
Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Monopar Therapeutics, Inc.'s net income of -$3.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNPRMonopar Therapeutics, Inc.-- -- -- -$3.4M INFUInfuSystem Holdings, Inc.1.30x 33.15x $36.5M $2.3M
-
Which has Higher Returns MNPR or VNRX?
VolitionRX Ltd. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of -862.39%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MNPRMonopar Therapeutics, Inc.-- -$0.48 $141.6M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About MNPR or VNRX?
Monopar Therapeutics, Inc. has a consensus price target of $112.00, signalling upside risk potential of 77.41%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 560.66%. Given that VolitionRX Ltd. has higher upside potential than Monopar Therapeutics, Inc., analysts believe VolitionRX Ltd. is more attractive than Monopar Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNPRMonopar Therapeutics, Inc.10 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is MNPR or VNRX More Risky?
Monopar Therapeutics, Inc. has a beta of 1.457, which suggesting that the stock is 45.666% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock MNPR or VNRX?
Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNPR or VNRX?
Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Monopar Therapeutics, Inc.'s net income of -$3.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 22.82x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNPRMonopar Therapeutics, Inc.-- -- -- -$3.4M VNRXVolitionRX Ltd.22.82x -- $627.3K -$5.4M
-
Which has Higher Returns MNPR or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of 3.93%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital MNPRMonopar Therapeutics, Inc.-- -$0.48 $141.6M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About MNPR or XTNT?
Monopar Therapeutics, Inc. has a consensus price target of $112.00, signalling upside risk potential of 77.41%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.94%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Monopar Therapeutics, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Monopar Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNPRMonopar Therapeutics, Inc.10 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is MNPR or XTNT More Risky?
Monopar Therapeutics, Inc. has a beta of 1.457, which suggesting that the stock is 45.666% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock MNPR or XTNT?
Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNPR or XTNT?
Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Monopar Therapeutics, Inc.'s net income of -$3.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 66.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 0.74x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNPRMonopar Therapeutics, Inc.-- -- -- -$3.4M XTNTXtant Medical Holdings, Inc.0.74x 66.86x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
